Article Text

Download PDFPDF
4CPS-087 Assessment of the direct acting antivirals used to treat the hepatitis c virus genotype 1 infection in a tertiary hospital
  1. L Villalobos Torres,
  2. JC del Río Valencia,
  3. R Asensi Díez,
  4. I Muñoz Castillo
  1. Hospital Universitario Carlos Haya, UGC Farmacia Hospitalaria, Malaga, Spain


Background Hepatitis C is a serious disease with high prevalence, leading the causes of liver transplantation. The development of well-tolerated and highly effective direct-acting antivirals (DAAs) for hepatitis C virus (HCV) has dramatically changed the therapeutic landscape.

Purpose Assessing the effectiveness of sofosbuvir/ledipasvir (SOF/LDV), dasabuvir/paritaprevir/ombitasvir/ritonavir (DSV/PTV+R/OBV) and sofosbuvir/simeprevir (SOF+SIM) used in the treatment of the hepatitis C virus genotype-1 infection.

Material and methods Retrospective and observational study during 2015. Inclusion criteria: patients with HCV genotype-1 infection treated for 12 weeks either with SOF/LDV or SOF+SMV or PTV+R/OBV/DSV during study period. Exclusion criteria: patients with no data available, deaths or without therapeutic adherence. Outcomes collected: demographics: age and sex. Clinical data: basal viral load (BVL), SVR at week 12 (SVR12), defined as HCV RNA titres lower than 15 IU/mL. METAVIR score: F0 to F4. Subgenotype, liver transplant, HIV co-infection, previous treatments for HCV. Data were collected from the medical records of patients.

Results Treatment with SOF/LDV: 39 patients were included (64.1% males) with a mean age of 60.3±9.1 years. Subgenotypic distribution was: 15.4% gt-1, 28.2% gt. 1-A, 56.4% gt. 1-B. According to METAVIR score: F4 to F3 (74.35%), F2 to F1 (25.65%). 17.9% patients were HIV-coinfected and 25.6% were liver transplanted. 51.3% were pretreated with ribavirin/peginterferon and 76.9%% had BVL>than 800,000 UI/ml. All patients (39) achieved SVR12.

Treatment with PTV+R/OBV/DSV: 52 patients (67.32% male) were included with mean age 55.2±10 years. Subgenotypic distribution: 11.5% gt-1, 21.1% gt. 1-A, 67.4% gt. 1-B. Degree of fibrosis: F4 to F3 (75%), F2 to F1 (25%). HIV-coinfected patients 30.8%, and 30.7% pretreated with ribavirin/peginterferon. 57.7% had BVL>800,000 UI/ml. 98% (51/52) patients achieved SVR12.

Treatment with SOF+SMV: 61 patients (59% males) were included, with mean age of 56.3±10 years. Subgenotypic distribution: 23% gt-1, 21.3% gt. 1-A, 55.7% gt. 1-B. METAVIR score: F4 to F3 (88.5%). F2 to F1 (11.5%). 70.5% had BVL>800,000 UI/ml. 16.4% were coinfected, and 65.6% pretreated. 90.2% (55/61) achieved SVR12.

Conclusion The SVR12 rates achieved in this study with the treatments SOF/LDV, SOF/SMV and PTV/OBV/r±RBV match the results obtained in published clinical trials ION–1,2,3; SAPPHIRE 1–2, PEARL 2–3–4, TURQUOISE 2–3 and COSMOS/OPTIMIST, respectively. These results indicate an excellent response to the AADs, and allow us to see a horizon of the eradication of VHC disease.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.